Showing 261-270 of 3281 results for "".
- INTerpath-001: Intismeran Plus Pembrolizumab Meets Dual Phase 3 Melanoma Endpointshttps://practicaldermatology.com/news/intismeran-plus-pembrolizumab-meets-dual-phase-3-melanoma-endpoints/2488176/Merck and Moderna reported positive topline results from the phase 3 INTerpath-001 trial evaluating intismeran autogene (V940; mRNA-4157) plus pembrolizumab (Keytruda) as adjuvant therapy for completely resected stage IIB-IV cutaneous melanoma. The individualized mRNA-based neoantigen ther
- Merz Aesthetics Announces FDA Clearance of Ultherapy PRIME for Knee Skin Laxityhttps://practicaldermatology.com/news/merz-aesthetics-announces-fda-clearance-of-ultherapy-prime-for-knee-skin-laxity/2488072/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME (Merz Aesthetics) to improve the appearance of skin laxity on the knees, according to an announcement from the company. Merz Aesthetics said the clearance makes Ultherapy PRIME the first energy-based aesthetic device wit
- FDA Approves Tudriqev Plus Nivolumab for Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-tudriqev-plus-nivolumab-for-advanced-melanoma/2488043/The FDA has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg; Replimune, Inc.) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed on a programmed death receptor-1 (PD-1)–blocking antibody-based regimen, according
- Adalimumab Leads Cost-Efficiency Analysis of Approved HS Biologics Across Five Countrieshttps://practicaldermatology.com/news/adalimumab-leads-cost-efficiency-analysis-of-approved-hs-biologics-across-five-countries/2488023/Adalimumab offers the most favorable balance of cost and clinical efficacy among currently approved monoclonal antibody therapies for moderate-to-severe hidradenitis suppurativa (HS), according to a new economic evaluation in JAM
- Comparative Study Finds No Significant Melanoma Mortality Reduction From German Screening Initiativehttps://practicaldermatology.com/news/comparative-study-finds-no-significant-melanoma-mortality-reduction-from-german-screening-initiative/2487471/A study of a German nationwide skin cancer screening (SCS) program showed reduced melanoma mortality compared with neighboring European countries that do not have population-based screening programs. Germany launched its nationwide SCS program in 2008, which included adults aged 35 years a
- Randomized Trial Evaluates Educational Delivery Methods for Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/randomized-trial-evaluates-educational-delivery-methods-for-pediatric-atopic-dermatitis/2487170/A randomized controlled trial published online in Pediatric Dermatology found that video-based therapeutic patient education (TPE) did not significantly outperform standard educational handouts for pediatric atopic dermatiti
- Global Skin Cancer Burden Projected to Rise Through 2050: Studyhttps://practicaldermatology.com/news/global-skin-cancer-burden-projected-to-rise-through-2050/2487086/A new research letter published online in JAMA Dermatology highlights widening global disparities in skin cancer burden and projects continued increases in melanoma, cutaneous squamous cell carcinoma (cSCC), and basal cell c
- Rapid Weight Loss Brings Expanding Soft Tissue Concerns to Dermatologyhttps://practicaldermatology.com/news/rapid-weight-loss-brings-expanding-soft-tissue-concerns-to-dermatology/2486936/A new analysis suggests rapid weight loss from GLP-1 agents, bariatric surgery, or lifestyle change is associated with measurable declines in skin elasticity and soft tissue volume.Rapid and intentional weight loss (driven by bariatric surgery, glucagon-l
- Exosomes in Dermatology: Emerging Adjuncts With Uncertain Standardizationhttps://practicaldermatology.com/news/exosomes-in-dermatology-emerging-adjuncts-with-uncertain-standardization/2486899/A recent narrative synthesized evidence from 2020 to 2025 on exosome-based therapeutics, highlighting their expanding role in dermatology and regenerative medicine. Across dermatologic applications, the authors wrote, precli
- Imaging Bests Exam in Detecting Nodal Metastases in High-Risk cSCChttps://practicaldermatology.com/news/imaging-bests-exam-in-detecting-nodal-metastases-in-high-risk-cscc/2486802/Ultrasonography and computed tomography (CT) outperformed physical examination for detecting baseline nodal metastases in high-risk cutaneous squamous cell carcinoma (cSCC). Investigators for the prospective, multicenter diagnostic study evaluated baseline staging modalities for detecting